Liesbeth Reneman

Liesbeth Reneman

Auto-generated profile, based on publicly available information

Liesbeth Reneman

Amsterdam UMC, location AMC, Department of Radiology and Nuclear Medicine, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2001 in The Lancet
Verified
Journal Article
Closed access
LRLiesbeth Reneman
Liesbeth Reneman
JBJan Booij
Jan Booij
KBKora de Bruin
Kora de Bruin
JRJohannes B Reitsma
Johannes B Reitsma
FWFrederik A de Wolff
Frederik A de Wolff
WBWim van Den Brink
Wim van Den Brink

23 February 2000 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
LRL. Reneman
L. Reneman
JBJ. Booij
J. Booij
BSB. Schmand
B. Schmand
WBW. van Den Brink
W. van Den Brink
BGB. Gunning
B. Gunning

1 October 2001 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
LRLiesbeth Reneman
Liesbeth Reneman
JLJules Lavalaye
Jules Lavalaye
BSBen Schmand
Ben Schmand
FWFrederik A. de Wolff
Frederik A. de Wolff
WBWim van Den Brink
Wim van Den Brink
JBJan Booij
Jan Booij
ALTHOUGH GENERALLY regarded as relatively safe, the popular recreational drug 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") has increasingly been shown to lead to toxic effects on brain serotonin (5-HT) neurons in animals and possibly in humans. In animals, damage to 5-HT neurons has been demonstrated by reductions in various markers unique to 5-HT axons, including the density of 5-HT transporters (SERTs).1-5 Since the SERT is located on the presynaptic axons and axon terminals of 5-HT neurons, it is considered to be a reliable marker of 5-HT neurotoxic changes. With the development of imaging techniques such as positron emission tomography and single-photon emission computed tomography (SPECT), it is now possible to measure SERT densities in the human brain. Recent imaging studies have shown decreases in central SERTs in MDMA-treated primates and human MDMA users.6-8

1 April 2019 in Medical Image Analysis
Verified
Journal Article
Closed access
KLKai Lønning
Kai Lønning
PPPatrick Putzky
Patrick Putzky
JSJan-Jakob Sonke
Jan-Jakob Sonke
LRLiesbeth Reneman
Liesbeth Reneman
MCMatthan W.A. Caan
Matthan W.A. Caan
MWMax Welling
Max Welling

1 March 2002 in Neuropsychopharmacology
Verified
Journal Article
Closed access
LRLiesbeth Reneman
Liesbeth Reneman
EEErik Endert
Erik Endert
KBKora De Bruin
Kora De Bruin
JLJules Lavalaye
Jules Lavalaye
MFMathijs G Feenstra
Mathijs G Feenstra
JBJan Booij
Jan Booij

1 September 2016 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
ASAnouk Schrantee
Anouk Schrantee
HTHyke G. H. Tamminga
Hyke G. H. Tamminga
CBCheima Bouziane
Cheima Bouziane
MBMarco A. Bottelier
Marco A. Bottelier
EBEsther E. Bron
Esther E. Bron
LRLiesbeth Reneman
Liesbeth Reneman
Methylphenidate hydrochloride is the most frequently prescribed medication for the treatment of attention-deficit/hyperactivity disorder (ADHD). It effectively reduces symptoms of inattention, hyperactivity, and impulsivity in up to 80% of children with ADHD.1 Methylphenidate increases extracellular dopamine (DA) levels in the brain by blocking the DA transporters in the synapse.2 Its short-term safety has been documented in many studies, and its efficacy is among the highest of all psychiatric medications.3 However, despite its prevalent use among children and adolescents, little is known about lasting effects of methylphenidate on the developing DAergic system.3-5